Neurocrine Biosciences (NBIX) navigates a dynamic market with INGREZZA's success, pipeline expansion, and strategic financial moves. A comprehensive analysis.
Analysis of Neurocrine Biosciences (NBIX): INGREZZA's data, CRENESSITY launch, share repurchase, analyst outlook, and pipeline. Get insights on NBIX stock.
Neurocrine Biosciences faces a complex landscape, balancing INGREZZA's success with CRENESSITY's launch and pipeline development. Analyst scrutiny and market volatility require strategic navigation for sustained growth.
Neurocrine Biosciences navigates growth and volatility in 2025 with CRENESSITY launch, INGREZZA growth, and pipeline advancements. Analyst sentiment is mixed, impacting market performance.
Neurocrine Biosciences (NBIX) navigates mixed Q4 results, CRENESSITY launch, and analyst shifts. INGREZZA drives revenue, CRENESSITY offers growth. Monitor KPIs.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.